Cargando…

Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer

Identification of novel effective early diagnostic biomarkers may provide alternative strategies to reduce the mortality for non-small cell lung cancer (NSCLC) patients. Circulating long non-coding RNAs (lncRNAs) have emerged as a new class of promising cancer biomarkers. Our study aimed to identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Shuai, Xiang, Ying, Guo, Xiaoping, Zhang, Yao, Li, Chengying, Xie, Weijia, Wu, Na, Wu, Long, Cai, Tongjian, Ma, Xiangyu, Yu, Zubin, Bai, Li, Li, Yafei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793881/
https://www.ncbi.nlm.nih.gov/pubmed/33425713
http://dx.doi.org/10.3389/fonc.2020.537120
_version_ 1783634088627798016
author Yuan, Shuai
Xiang, Ying
Guo, Xiaoping
Zhang, Yao
Li, Chengying
Xie, Weijia
Wu, Na
Wu, Long
Cai, Tongjian
Ma, Xiangyu
Yu, Zubin
Bai, Li
Li, Yafei
author_facet Yuan, Shuai
Xiang, Ying
Guo, Xiaoping
Zhang, Yao
Li, Chengying
Xie, Weijia
Wu, Na
Wu, Long
Cai, Tongjian
Ma, Xiangyu
Yu, Zubin
Bai, Li
Li, Yafei
author_sort Yuan, Shuai
collection PubMed
description Identification of novel effective early diagnostic biomarkers may provide alternative strategies to reduce the mortality for non-small cell lung cancer (NSCLC) patients. Circulating long non-coding RNAs (lncRNAs) have emerged as a new class of promising cancer biomarkers. Our study aimed to identify circulating lncRNAs for diagnosing NSCLC. A total 528 plasma samples were continuously collected and allocated to four progressive phases: discovery, training, verification, and expansion phases. The expression of candidate lung cancer related lncRNAs were detected using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). We identified a 4-lncRNA panel (RMRP, NEAT1, TUG1, and MALAT1) that provided a high diagnostic value in NSCLC (AUC = 0.86 and 0.89 for training and verification phase, respectively). Subgroup analyses showed that the 4-lncRNA panel had a sensitivity of 78.95% [95% confidence interval (CI) = 62.22%–89.86%] in stage I-II patients and 75.00% (95% CI = 52.95%–89.40%) in patients with small tumor size (≤3cm). Notably, the sensitivity of 4-lncRNA panel was significantly higher than that of routine protein panels in adenocarcinoma (CEA, CA125, and CYFRA21-1, 86.30% vs. 73.96%). Adding 4-lncRNA to protein markers significantly improved the diagnostic capacity in both adenocarcinoma (AUC=0.85, 95% CI = 0.78–0.91) and squamous cell carcinoma (AUC=0.93, 95% CI = 0.86–0.97). In conclusion, we identified a plasma 4-lncRNA panel that has considerable clinical value in diagnosing NSCLC. The 4-lncRNA panel could improve the diagnostic values of routine tumor protein markers in diagnosing NSCLC. Circulating lncRNAs could be used as promising candidates for NSCLC diagnosis.
format Online
Article
Text
id pubmed-7793881
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77938812021-01-09 Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer Yuan, Shuai Xiang, Ying Guo, Xiaoping Zhang, Yao Li, Chengying Xie, Weijia Wu, Na Wu, Long Cai, Tongjian Ma, Xiangyu Yu, Zubin Bai, Li Li, Yafei Front Oncol Oncology Identification of novel effective early diagnostic biomarkers may provide alternative strategies to reduce the mortality for non-small cell lung cancer (NSCLC) patients. Circulating long non-coding RNAs (lncRNAs) have emerged as a new class of promising cancer biomarkers. Our study aimed to identify circulating lncRNAs for diagnosing NSCLC. A total 528 plasma samples were continuously collected and allocated to four progressive phases: discovery, training, verification, and expansion phases. The expression of candidate lung cancer related lncRNAs were detected using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR). We identified a 4-lncRNA panel (RMRP, NEAT1, TUG1, and MALAT1) that provided a high diagnostic value in NSCLC (AUC = 0.86 and 0.89 for training and verification phase, respectively). Subgroup analyses showed that the 4-lncRNA panel had a sensitivity of 78.95% [95% confidence interval (CI) = 62.22%–89.86%] in stage I-II patients and 75.00% (95% CI = 52.95%–89.40%) in patients with small tumor size (≤3cm). Notably, the sensitivity of 4-lncRNA panel was significantly higher than that of routine protein panels in adenocarcinoma (CEA, CA125, and CYFRA21-1, 86.30% vs. 73.96%). Adding 4-lncRNA to protein markers significantly improved the diagnostic capacity in both adenocarcinoma (AUC=0.85, 95% CI = 0.78–0.91) and squamous cell carcinoma (AUC=0.93, 95% CI = 0.86–0.97). In conclusion, we identified a plasma 4-lncRNA panel that has considerable clinical value in diagnosing NSCLC. The 4-lncRNA panel could improve the diagnostic values of routine tumor protein markers in diagnosing NSCLC. Circulating lncRNAs could be used as promising candidates for NSCLC diagnosis. Frontiers Media S.A. 2020-12-07 /pmc/articles/PMC7793881/ /pubmed/33425713 http://dx.doi.org/10.3389/fonc.2020.537120 Text en Copyright © 2020 Yuan, Xiang, Guo, Zhang, Li, Xie, Wu, Wu, Cai, Ma, Yu, Bai and Li http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yuan, Shuai
Xiang, Ying
Guo, Xiaoping
Zhang, Yao
Li, Chengying
Xie, Weijia
Wu, Na
Wu, Long
Cai, Tongjian
Ma, Xiangyu
Yu, Zubin
Bai, Li
Li, Yafei
Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
title Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
title_full Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
title_fullStr Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
title_full_unstemmed Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
title_short Circulating Long Noncoding RNAs Act as Diagnostic Biomarkers in Non-Small Cell Lung Cancer
title_sort circulating long noncoding rnas act as diagnostic biomarkers in non-small cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793881/
https://www.ncbi.nlm.nih.gov/pubmed/33425713
http://dx.doi.org/10.3389/fonc.2020.537120
work_keys_str_mv AT yuanshuai circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer
AT xiangying circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer
AT guoxiaoping circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer
AT zhangyao circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer
AT lichengying circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer
AT xieweijia circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer
AT wuna circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer
AT wulong circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer
AT caitongjian circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer
AT maxiangyu circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer
AT yuzubin circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer
AT baili circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer
AT liyafei circulatinglongnoncodingrnasactasdiagnosticbiomarkersinnonsmallcelllungcancer